Table of Content



Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Segment Scope
1.1.2 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Target Population & Patient Stratification (Top-down estimation): mODEL 1
1.6.2 Assumptions /Key Considerations
1.6.3 Commodity Flow Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Abbreviations
1.10 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.1.1 U.S. Veterinary Oncology market Outlook, 2017-2030 (USD Million)
2.2 U.S. Veterinary Oncology Market Summary, 2021
2.3 Segment Outlook
Chapter 3 Veterinary Oncology Market Variables Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping by Technology, 2021
3.3 U.S. Veterinary Oncology Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increasing prevalence of cancer in pets
3.3.1.2 Increasing R&D in pet cancer therapy
3.3.1.3 Growing focus on animal safety
3.3.1.4 Growing demand for pet insurance
3.3.1.5 Technological advancements in pet cancer treatment
3.3.1.6 Increase in pet adoption
3.3.2 Market restraint analysis
3.3.2.1 High cost of pet cancer treatments
3.3.2.2 Increasing incidence of pet abandonment and euthanasia
3.3.2.3 Adverse effects of drugs used for pet cancer treatment
3.3.3 Industry challenges
3.3.3.1 Illegal veterinary medicines
3.4 Industry Analysis - Porter’s
3.4.1 Supplier Power: Moderate
3.4.2 Buyer Power: Low to Moderate
3.4.3 Threat of Substitutes: Moderate to High
3.4.4 Threat of New entrants: Moderate
3.4.5 Competitive Rivalary: High
3.5 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
3.5.1 Political and Legal landscape
3.5.2 Economic Landscape
3.5.3 Technology Landscape
3.5.4 Social Landscape
3.6 User Perspective Analysis
3.6.1 List of Key End Users
3.6.2 Consumer behavior
3.6.3 Market Influencer Analysis
3.7 Regulatory Framework
3.7.1 Regulatory Landscape
3.7.2 Standards & compliances
3.8 Technology Overview
3.8.1 Technology timeline analysis
3.9 Product Pipeline Analysis
3.10 Pricing Trend Analysis
Chapter 4 COVID-19 Impact
4.1 Covid-19 Prevalence
4.2 Impact of COVID-19 on the Market
4.3 Regulatory/Policy Changes
4.4 Strategies Adopted by Market Players
Chapter 5 Competitive Analysis
5.1 Market Participation Categorization
5.2 Competitive Analysis
5.2.1 Company market position analysis
5.2.2 Market leader
5.2.3 Innovators
5.3 Market Entry Strategies
Chapter 6 U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
6.1 Therapy Market Share Analysis, 2021 & 2030
6.2 Therapy Dashboard
6.3 Surgery
6.3.1 Surgery market estimates and forecasts, 2017 - 2030 (USD Million)
6.4 Radiology
6.4.1 Radiology market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2 Stereotactic Radiation Therapy
6.4.2.1 Stereotactic radiation therapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.2 Gamma knife
6.4.2.2.1 Gamma Knife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.3 Linear accelerators
6.4.2.3.1 LINAC market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.4 Particle beam
6.4.2.4.1 PBRT market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.5 Cyberknife
6.4.2.5.1 CyberKnife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.3 Brachytherapy
6.4.3.1 Brachytherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.4 Others
6.4.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
6.5 Chemotherapy
6.5.1 Chemotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.6 Immunotherapy
6.6.1 Immunotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.7 Others
6.7.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
Chapter 7 U.S. Veterinary Oncology Market: Animal Type Estimates & Trend Analysis
7.1 Animal Type Market Share Analysis, 2021 & 2030
7.2 Animal Type Dashboard
7.3 Canine
7.3.1 Canine market estimates and forecasts, 2017 - 2030 (USD million)
7.3.2 Lymphoma
7.3.2.1 Lymphoma market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.3 Mast Cell Cancer
7.3.3.1 Mast Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.4 Mammary and Squamous Cell Cancer
7.3.4.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.5 Others
7.3.5.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.4 Feline
7.4.1 Feline market estimates and forecasts, 2017 - 2030 (USD million)
7.4.2 Mammary and Squamous Cell Cancer
7.4.2.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.3 Others
7.4.3.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.5 Others
7.5.1 Others market estimates and forecasts, 2017 - 2030 (USD million)
Chapter 8 Company Profiles
8.1 Zoetis
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Boehringer Ingelheim GmbH
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Elanco
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 PetCure Oncology
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Accuray Incorporated
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Varian Medical Systems, Inc.
8.6.1 Company overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Morphogenesis, Inc.
8.7.1 Company overview
8.7.2 Product benchmarking
8.7.3 Strategic initiatives
8.8 Karyopharm Therapeutics, Inc.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Regeneus Ltd.
8.9.1 Company Overview
8.9.2 Product Benchmarking
8.9.3 Strategic Initiatives
8.10 OHC (One Health Company)
8.10.1 Company overview
8.10.2 Product benchmarking
8.10.3 Strategic initiatives
8.11 List of Market Participants



List of Figures

List of Figures

Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Target Population & Treatment Rate
Fig. 10 Treatment Cost analysis
Fig. 11 Commodity flow analysis
Fig. 12 U.S. Veterinary Oncology market revenue (USD Million)
Fig. 13 U.S. Veterinary Oncology Market Snapshot
Fig. 14 Segment Outlook, 2021
Fig. 15 Parent market outlook
Fig. 16 Ancillary market outlook
Fig. 17 Penetration &growth prospect mapping by Technology, 2021
Fig. 18 U.S. Veterinary Oncology market dynamics
Fig. 19 U.S. Veterinary Oncology market driver impact
Fig. 20 Total pet expenditure in the U.S., 2010 - 2019, Billion
Fig. 21 Estimated pet population in the U.S., 2015 - 2019, Million
Fig. 22 U.S. Veterinary Oncology market restraint impact
Fig. 23 Consumer behavior analysis
Fig. 24 Market influencing analysis
Fig. 25 Technology timeline analysis
Fig. 26 Covid - 19 prevalence
Fig. 27 Market participant categorization
Fig. 28 Veterinary oncology company market position analysis
Fig. 29 Market entry strategies
Fig. 30 U.S. Veterinary Oncology market: Therapy movement analysis
Fig. 31 U.S. Veterinary Oncology Market: Therapy Dashboard
Fig. 32 Surgery market, 2017 - 2030 (USD Million)
Fig. 33 Radiology market, 2017 - 2030 (USD Million)
Fig. 34 Veterinary Stereotactic radiation therapy market, 2017 - 2030 (USD Mullion)
Fig. 35 Gamma knife market revenues, 2017 - 2030 (USD Million)
Fig. 36 LINAC market revenues, 2017 - 2030 (USD Million)
Fig. 37 PBRT market revenues, 2017 - 2030 (USD Million)
Fig. 38 CyberKnife market revenues, 2017 - 2030 (USD Million)
Fig. 39 Brachytherapy market, 2017 - 2030 (USD Mullion)
Fig. 40 Others market, 2017 - 2030 (USD Mullion)
Fig. 41 Chemotherapy market, 2017 - 2030 (USD Million)
Fig. 42 Immunotherapy market, 2017 - 2030 (USD Million)
Fig. 43 Others market, 2017 - 2030 (USD Million)
Fig. 44 U.S. Veterinary Oncology market: Animal Type movement analysis
Fig. 45 U.S. Veterinary Oncology Market: Animal Type Dashboard
Fig. 46 Canine market, 2017 - 2030 (USD Million)
Fig. 47 Lymphoma market, 2017 - 2030 (USD Million)
Fig. 48 Mast cell cancer market, 2017 - 2030 (USD Million)
Fig. 49 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 50 Others market, 2017 - 2030 (USD Million)
Fig. 51 Feline market, 2017 - 2030 (USD Million)
Fig. 52 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 53 Others market, 2017 - 2030 (USD Million)
Fig. 54 Others market, 2017 - 2030 (USD Million)

List of Tables

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. U.S. Pet Ownership, 2019 - 2020 (Millions)
Table 4. U.S. Pet Expenditure, 2019 - 2020 (USD)
Table 5. Clinical Trials in progress for companion animals by UC Davis in 2018
Table 6. U.S. Veterinary Oncology Market, 2017 - 2030 (USD Million)
Table 7. U.S. Veterinary Oncology Market, by therapy, 2017 - 2030 (USD Million)
Table 8. U.S. Veterinary radiology Market, by type, 2017 - 2030 (USD Million)
Table 9. U.S. Veterinary stereotactic radiation therapy Market, by type, 2017 - 2030 (USD Million)
Table 10. U.S. Veterinary Oncology Market, by animal type, 2017 - 2030 (USD Million)
Table 11. U.S. feline oncology Market by cancer type, 2017 - 2030 (USD Million)
Table 12. U.S. canine oncology Market by cancer type, 2017 - 2030 (USD Million)